



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

August 29, 2018

Andrea Pfeifer  
Chief Executive Officer  
AC Immune SA  
EPFL INNOVATION PARK  
Building B  
1015 Lausanne  
Switzerland

**Re: AC Immune SA**  
**Registration Statement on Form F-3**  
**Filed August 24, 2018**  
**File No. 333-227016**

Dear Ms. Pfeifer:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Irene Paik at 202-551-6553 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Healthcare & Insurance

cc: Derek J. Dostal - Davis Polk & Wardwell LLP